Valinor, a San Francisco-based AI company focused on improving clinical trial outcomes through machine-learning-driven patient response prediction, announced $13 million in seed funding to scale its multimodal platform for patient selection. The round was led by CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners, with additional participation from angel investors and operators, including Charlie Songhurst, Surya Midha, Axel Ericsson, and Kyle Harrison.
The company is developing proprietary machine learning models designed to increase the probability of clinical trial success by helping drug developers more precisely identify which patients are likely to respond to a given therapy. Valinor said its models are trained on matched datasets that combine patient-derived multi-omic samples with treatment outcomes, enabling response prediction across disease indications and supporting faster, more targeted enrollment decisions.
Valinor positioned its approach as a way for pharmaceutical partners to distinguish responders from non-responders while also surfacing biology associated with response. The company said these insights can help redefine target patient populations, strengthen trial design, and potentially reveal new indications using real-world patient data.
Valinor said the new capital will be used to expand its proprietary matched omics and clinical outcome datasets and to advance its AI models to support more data-driven drug development decisions. The company also plans to recruit additional machine learning talent to grow its San Francisco-based team as it scales platform development and customer work in patient selection modeling.
KEY QUOTES:
“Our models are built to surface meaningful features that underlie patient response. We believe this approach will empower our pharmaceutical partners to improve clinical trial success rates, cut R&D costs and, most importantly, speed the delivery of life-saving medicines to patients,”
“With this funding, we are accelerating the expansion of our proprietary matched omics and clinical outcome datasets and advancing our AI models that allow our pharma partners to make smarter, data-driven decisions in drug development.”
Joshua Pacini, Founder and Chief Executive Officer, Valinor
“As early backers of tech bio pioneers like Recursion, we’ve seen AI become the driving force accelerating the next generation of drug development. Valinor pushes the frontier further with an AI-first, disease-focused platform training on exceptional clinical data. We believe this approach can meaningfully improve clinical trial success,”
Brittany Walker, General Partner, CRV
